This systematic review evaluates the use of testosterone therapy (TTh) in men with prostate cancer (PCa), focusing on whether TTh increases the risk of disease progression. The review found that recent evidence suggests TTh does not elevate the risk of prostate cancer or lead to more aggressive disease, especially when
